However, in a recent study evaluating ERBB2 mutations using ctDNA in patients with advanced breast cancer, the frequency of ERBB2 mutations was 8.9% and this was higher in HER2-positive tumors than in HER2-negative tumors [26]. This evidence concerns the gene ERBB2 and breast cancer.